NCT05573217招募中不适用
The Utility of Cell-free DNA Methylation Markers for the Response Prediction of Systemic Treatment for Hepatocellular Carcinoma
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 180
- 试验地点
- 1
- 主要终点
- Evaluate efficacy
研究概览
简要总结
The subjects of this study were patients with liver cancer diagnosed by physicians according to AASLD clinical criteria or pathological biopsy.
Those who plan to receive systemic drug treatment for liver cancer in National Taiwan University Hospital include Nexavar, Lenvatinib, Avastin, Tecentriq, Strivarga, Cabometyx, Cyramza, Nivolunab, Pembrolizumab, and Yervoy. Weak and uncooperative patients were excluded from blood tests, which were performed with full informed consent for relevant tumor markers (AFP ,PIVKA-II and methylation analysis). The data are then counted and compared.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients diagnosed with liver cancer by AASLD clinical criteria or pathological slides Patients planning to receive systemic drug therapy for liver cancer at National Taiwan University Hospital include Nexavar, Lenvatinib, Avastin, Tecentriq, Strivarga, Cabometyx, Cyramza, Nivolunab, Pembrolizumab, and Yevoy.
- •Over 20 years old.
- •In the case of informed consent, willing to sign the consent form of the subjects.
排除标准
- •Patients who are weak and unable to cooperate with blood test.
- •Kidney dysfunction, serum creatinine greater than 1.5 x UNL (normal value) and no hemodialysis treatment, who are judged to be unwell for computed tomography or MRI contrast agent injection.
结局指标
主要结局
Evaluate efficacy
时间窗: 3 month after treatment
Correlation of methylation profiling results and tumor treatment response.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
The Utility of Cell-free Methylation Markers in Blood for Hepatocellular CarcinomaSerum Tumor MarkersNCT05576571National Taiwan University Hospital90
Unknown
不适用
Cell-free DNA Methylation Markers for Cancer ScreeningCancer ScreeningNCT03096938Sun Yat-sen University15,000
招募中
不适用
Validation of DNA Methylation Markers for Universal and Site-specific Guided Cancer Detection, VANGUARD StudyHematopoietic and Lymphatic System NeoplasmMalignant Solid NeoplasmNCT06304168Mayo Clinic6,150
已完成
不适用
The Methylation Phenotype Screening and Determination Mode Study of Liver Cancer Prognosis Related GeneHepatocellular Carcinoma;Radical Hepatic Resection;NCT01786980Eastern Hepatobiliary Surgery Hospital300
Unknown
不适用
Studying DNA in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial CancerOvarian CancerNCT00900289Liz-Anne Lewsley1,000